Evaluation of the Pharmacokinetic Properties and the Tolerance of Raltegravir During the Third Trimester of Pregnancy

Trial Profile

Evaluation of the Pharmacokinetic Properties and the Tolerance of Raltegravir During the Third Trimester of Pregnancy

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs Raltegravir (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Acronyms RalFE
  • Most Recent Events

    • 18 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 11 Jul 2016 Status changed from recruiting to active, no longer recruiting.
    • 28 Oct 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top